Sweden · Delayed Price · Currency is SEK RaySearch Laboratories AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw a 20% sales decline due to currency and timing of large deals, but profitability stayed strong with a 23% margin. Recurring revenue and order backlog remain robust, and momentum in RayCare and proton therapy segments supports a positive outlook.
Fiscal Year 2025
-
Record net sales and profitability were achieved in 2025, driven by strong license and recurring revenues, major clinical milestones, and robust global demand. The company is confident in reaching a 25% EBIT margin in 2026 and has raised its dividend proposal, with new financial targets to be set during the year.
-
Record Q3 net sales and EBIT margin driven by strong license and support revenue growth, major customer wins, and robust demand for oncology software. Order intake rose 17%, with Pinnacle system replacements accelerating and RayCare interest intensifying.
-
Q2 2025 saw a 4% sales decline due to delayed orders and tough year-over-year comparisons, but strong July order intake and a robust backlog support continued growth expectations. Operating margin was 12% (17% adjusted), and management maintains a 25% margin target by 2026.
-
Record Q1 sales and order intake drove a 29% revenue increase and a 23% operating margin, with strong growth in licenses and support. Major orders in China and Europe, new product launches, and a robust cash position support a positive outlook for margin expansion and continued growth.
Fiscal Year 2024
-
Record sales and operating profit were achieved in 2024, with strong license and support revenue growth, a robust cash position, and a proposed dividend increase. Market share remains high in key segments, and the outlook for 2025 is positive with a raised margin target.
-
Q3 2024 saw record sales and a 21% operating margin, with strong growth in license revenue and a robust cash position. RayCare's clinical adoption and new automation features expand market potential, while the operating margin target for 2026 was raised to at least 25%.
-
Record Q2 sales and operating profit were driven by strong license and support revenue growth, with a robust cash position and order backlog supporting a positive outlook. The company continues to invest in AI and product innovation, with major implementations and partnerships underway.